Elsevier Inc.

SHERPA: Unknown

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Bajorin
    Bajorin
  4. Rosenberg
    Rosenberg
  5. Iyer
    Iyer
  6. Solit
    Solit
  7. Feldman
    Feldman
  8. Morris
    Morris
  9. Slovin
    Slovin
  10. Voss
    Voss

Groups

  1. Genitourinary Oncology Service (384)
  2. Solid Tumor Oncology Division (384)
  3. Department of Medicine (383)
  4. GSK Faculty (92)
  5. Surgery (68)
  6. Survivorship Research (63)
  7. Urology (54)
  8. Hematologic Malignancies, Division of (49)
  9. Human Oncology and Pathogenesis Program (49)
  10. Department of Pathology and Laboratory Medicine (46)
Search Within
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (245)
  2. Meeting Abstract (120)
  3. Review (7)
  4. Conference Paper (6)
  5. Book Section (3)
  6. Editorial (2)
  7. Guidelines (1)
Groups
  1. Genitourinary Oncology Service (384)
  2. Solid Tumor Oncology Division (384)
  3. Department of Medicine (383)
  4. GSK Faculty (92)
  5. Surgery (68)
  6. Survivorship Research (63)

More Groups

People
  1. Robert Motzer (89)
  2. Howard Scher (72)
  3. Dean Bajorin (50)
  4. Jonathan Rosenberg (39)
  5. David Solit (33)
  6. Gopakumar Iyer (33)

More People

Years
  1. 2025 (9)
  2. 2024 (31)
  3. 2023 (12)
  4. 2022 (18)
  5. 2021 (11)
  6. 2020 (10)

More Years

Publications
  1. European Journal of Cancer (96)
  2. Clinical Genitourinary Cancer (63)
  3. Urologic Oncology: Seminars and Original Investigations (49)
  4. International Journal of Radiation Oncology, Biology, Physics (47)
  5. Seminars in Oncology (41)
  6. Hematology/Oncology Clinics of North America (10)

More Publications

Results (384)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Deleterious alterations in DNA damage response genes are associated with improved outcome in muscle-invasive bladder cancer patients treated with radiation-based bladder preservation
    Meeting Abstract

    Desai, N. B.; Iyer, G. I.; Cha, E. K.; Scott, S. N.; Hreiki, J.; Sfakianos, J.; Bagrodia, A.; Bochner, B. H.; Rosenberg, J. E.; Bajorin, D.; more...
    International Journal of Radiation Oncology, Biology, Physics (2015)

    Fulltext@MSK | Save
  • A molecular model for predicting overall survival in patients with metastatic clear cell renal carcinoma: Results from CALGB 90206 (Alliance)
    Journal Article

    Kim, H. L.; Halabi, S.; Li, P.; Mayhew, G.; Simko, J.; Nixon, A. B.; Small, E. J.; Rini, B.; Morris, M. J.; Taplin, M. E.; more...
    EBioMedicine (2015)

    Fulltext@MSK | Save
  • Precision medicine at Memorial Sloan Kettering Cancer Center: Clinical next-generation sequencing enabling next-generation targeted therapy trials
    Journal Article

    Hyman, D. M.; Solit, D. B.; Arcila, M. E.; Cheng, D. T.; Sabbatini, P.; Baselga, J.; Berger, M. F.; Ladanyi, M.
    Drug Discovery Today (2015)

    Fulltext@MSK | Save
  • Long-term safety with axitinib in previously treated patients with metastatic renal cell carcinoma
    Journal Article

    Rini, B. I.; Escudier, B.; Hariharan, S.; Roberts, W. G.; Tarazi, J.; Rosbrook, B.; Askerova, Z.; Deannuntis, L. L.; Motzer, R. J.
    Clinical Genitourinary Cancer (2015)

    Fulltext@MSK | Save
  • Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210)
    Meeting Abstract

    Rosenberg, J.; Petrylak, D.; Abidoye, O.; Van der Heijden, M. S.; Hofman-Censits, J.; Necchi, A.; O'Donnell, P. H.; Balmanoukian, A.; Loriot, Y.; Retz, M.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial
    Meeting Abstract

    Choueiri, T.; Escudier, B.; Powles, T.; Mainwaring, P.; Rini, B.; Donskov, F.; Hammers, H.; Hutson, T.; Roth, B.; Peltola, K.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • CheckMate 025: A randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Sharma, P.; Escudier, B.; McDermott, D. F.; George, S.; Hammers, H. J.; Srinivas, S.; Tykodi, S. S.; Sosman, J. A.; Procopio, G.; Plimack, E. R.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Assessment of genomic alterations in bladder adenocarcinoma and urachal adenocarcinoma
    Meeting Abstract

    Jordan, E.; Won, H.; Toubaji, A.; Bagrodia, A.; Desai, N.; Bajorin, D.; Rosenberg, J.; Bochner, B.; Kim, W.; Berger, M.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • RECORD-4 multicenter phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Asian versus non-Asian population subanalysis
    Meeting Abstract

    Yang, L.; Alyasova, A.; Ye, D.; Karpenko, A.; Li, H.; Alekseev, B.; Xie, L.; Kurteva, G.; Kowalyszyn, R.; Karyakin, O.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • A phase I/II study to assess the safety and efficacy of pazopanib (paz) and pembrolizumab (pembro) in patients (pts) with advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    McDermott, D. F.; Infante, J. R.; Chowdhury, S.; Voss, M. H.; Motzer, R. J.; Perini, R. F.; Morosky, A.; Zheng, F. F.; White, B. C.; Wang, Q.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save